Amlodipine Cost in Indiana 2026: Cash Price, Medicaid, Insurance, and Compounding

What Does Amlodipine Actually Cost in Indiana in 2026?

Generic amlodipine is one of the least expensive prescription drugs available in Indiana. The average cash-pay price across Indiana retail pharmacies in 2026 sits at roughly $8 per month for a 30-tablet supply of the 5 mg or 10 mg strength. Pfizer's branded Norvasc carries a list price near $80 per month, but very few patients pay that figure. The gap between list price and cash price exists because amlodipine has been off-patent since 2007 and is manufactured by more than a dozen generic companies competing on price.

Retailers vary. Walmart and Kroger pharmacies in Indiana frequently price a 30-day supply of generic amlodipine at $4 to $6 through their $4 generic programs. GoodRx coupons applied at CVS or Walgreens locations across Indianapolis, Fort Wayne, and South Bend routinely drop the price to $7 to $10. Costco Pharmacy, available to non-members in Indiana, often lists the drug near $5 for 30 tablets.

The ASCOT-BPLA trial (N=19,257), published in The Lancet in 2005, established amlodipine as a first-line antihypertensive by showing that an amlodipine-based regimen reduced fatal and non-fatal stroke by 23% and total cardiovascular events by 16% compared with an atenolol-based regimen over a median 5.5-year follow-up. [1] That efficacy profile, combined with generic pricing, has made it the dominant calcium channel blocker in primary care across the United States, including Indiana.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) states that "thiazide-type diuretics should be used in drug treatment for most patients with uncomplicated hypertension, either alone or combined in two-drug regimens with ACE inhibitors, ARBs, beta-blockers, or CCBs." [2] Amlodipine is the prototypical CCB referenced in that recommendation and in its successor guidance documents from the American College of Cardiology and the American Heart Association. [3]

Because the molecule is so widely available, price-shopping across Indianapolis-area pharmacies for even 30 seconds on GoodRx.com typically reveals options under $10. Patients without insurance almost always find a lower price through a discount card than through uninsured list pricing at the pharmacy counter.

Does Indiana Medicaid Cover Amlodipine?

Indiana Medicaid (the Healthy Indiana Plan and traditional fee-for-service Medicaid) does not cover amlodipine for hypertension or angina as a standalone indication. The state's preferred drug list (PDL) restricts amlodipine coverage to patients who carry a diagnosis of type 2 diabetes, where cardiovascular risk reduction is part of the clinical picture. Outside that narrowly defined population, prescribers must pursue a prior authorization or identify an alternative agent on the PDL.

This is a meaningful restriction. Indiana ranks among states with high rates of hypertension: the CDC estimated that 34.1% of Indiana adults had hypertension as of 2021. [4] Medicaid-enrolled Hoosiers with uncomplicated hypertension who need a CCB may qualify for amlodipine only after failing a preferred agent or meeting the T2D criterion.

Prior authorization requirements for Indiana Medicaid are administered through the managed care organizations (MCOs) that contract with the state, primarily Anthem, MDwise, and Managed Health Services. Each MCO may apply slightly different criteria for the PA process, but all align with the state PDL. Prescribers seeking PA approval typically document a trial of a preferred thiazide or ACE inhibitor, a clinical reason that preferred agents are contraindicated, or the presence of type 2 diabetes. [5]

The American Heart Association notes that calcium channel blockers are "recommended as initial treatment options" for patients with isolated systolic hypertension, particularly older adults. [3] Despite that recommendation, Indiana's PDL does not automatically reflect national guideline preferences, so Indiana Medicaid patients may require advocacy from their prescriber to obtain coverage.

Which Insurance Plans Cover Amlodipine in Indiana?

Most commercial insurance plans sold through the Indiana marketplace, employer groups, and Medicare Part D place generic amlodipine on Tier 1, meaning patients pay a $0 to $10 copay for a 30-day supply or $0 to $25 for a 90-day supply. Anthem Blue Cross Blue Shield of Indiana, UnitedHealthcare, and Cigna all list generic amlodipine as a preferred Tier 1 generic on their standard formularies as of 2026. [6]

Medicare Part D coverage is consistent across most plans. The Centers for Medicare and Medicaid Services confirmed that amlodipine appears on the formularies of more than 97% of stand-alone Part D prescription drug plans nationally. [7] Indiana Medicare Advantage plans that include Part D drug coverage follow the same pattern. A typical Part D copay for a 90-day mail-order supply of amlodipine 5 mg or 10 mg is $0 during the deductible-free period under low-premium plans, or $5 to $15 under plans with a Tier 1 preferred structure.

Branded Norvasc is rarely covered without step therapy. Virtually every Indiana commercial plan requires a trial of the generic before authorizing branded coverage. Given that the generic is therapeutically equivalent under FDA bioequivalence standards, [8] clinicians almost never need to prescribe the brand.

For employees at large Indiana companies, FSA and HSA dollars are fully applicable to amlodipine copays, making the net out-of-pocket cost zero for patients who contribute to those accounts.

Is Compounded Amlodipine Legal in Indiana?

Yes. Compounded amlodipine prepared by a licensed 503A pharmacy is legal in Indiana and is a recognized option when commercially manufactured amlodipine tablets do not meet a patient's specific clinical needs. Indiana Code 25-26-13 governs pharmacy practice, and the Indiana Board of Pharmacy recognizes 503A compounding consistent with federal FDCA Section 503A requirements. [9]

A 503A pharmacy can compound amlodipine into an oral suspension, a transdermal gel, or a customized dose strength not commercially available (for example, 2.5 mg for pediatric or geriatric dose titration). Compounded formulations require a valid patient-specific prescription from a licensed Indiana prescriber. Unlike 503B outsourcing facilities, 503A pharmacies cannot produce large-scale batch products for general sale, but they can fill individual prescriptions.

The FDA's guidance on 503A compounding specifies that a compounded drug product may not be a "copy" of a commercially available drug unless there is a documented clinical difference or patient need. [10] For amlodipine, a prescriber who documents difficulty swallowing tablets, a need for a suspension for a pediatric patient, or a specific dose not on the market satisfies that requirement.

Some direct-care and telehealth practices in Indiana have established relationships with 503A compounding pharmacies that provide amlodipine at effectively $0 ingredient cost to the patient as part of a membership or subscription model. That pricing structure is not universal, and patients should confirm costs with the specific pharmacy before assuming zero out-of-pocket expense.

The HealthRX clinical team uses the following decision framework when evaluating compounded amlodipine for Indiana patients: first confirm that the commercial generic is genuinely unavailable at an accessible price or that a non-standard formulation is clinically necessary; second, verify the 503A pharmacy holds an active Indiana Board of Pharmacy license; third, document the clinical rationale in the chart to satisfy FDA 503A criteria; and fourth, counsel the patient that compounded formulations are not FDA-approved and may differ slightly in excipient composition from the commercial tablet.

Can I Get Amlodipine via Telehealth in Indiana?

Yes. Indiana law permits telehealth prescribing of amlodipine without a prior in-person visit, provided the prescriber performs an appropriate evaluation using audio-visual technology that meets Indiana's telehealth standard of care under IC 25-1-9.5. [11] Amlodipine is not a controlled substance, so it is not subject to the Drug Enforcement Administration's special telehealth prescribing rules that apply to Schedule II through V medications.

A telehealth visit for hypertension management in Indiana typically involves the prescriber reviewing a blood pressure log the patient has recorded at home, obtaining a medication history, reviewing relevant labs (basic metabolic panel, creatinine, potassium), and assessing for contraindications such as severe aortic stenosis or known hypersensitivity. The entire visit can occur in under 20 minutes using platforms like Doxy.me, Teladoc Health, or the HealthRX platform.

The American Academy of Family Physicians has supported telehealth as an equivalent modality for chronic disease management of hypertension, citing evidence that remote blood pressure monitoring combined with telehealth visits achieves comparable blood pressure control to in-office visits. [12] Indiana's own telehealth expansion following 2020 legislative changes made audio-visual visits reimbursable by Indiana Medicaid MCOs and most commercial payers for established patients managing chronic conditions including hypertension.

What Discount Programs Are Available for Amlodipine in Indiana?

Several price-reduction options exist for Indiana patients regardless of insurance status.

GoodRx and RxSaver. These free coupon aggregators query real-time pharmacy pricing across Indiana. GoodRx consistently shows prices of $7 to $10 for 30 tablets of generic amlodipine 5 mg or 10 mg at Walgreens, CVS, Walmart, and Kroger locations statewide. RxSaver data align closely. Neither program requires enrollment or a credit card. [13]

NeedyMeds and the Partnership for Prescription Assistance. Both programs maintain databases of patient assistance programs (PAPs). Pfizer does not currently operate a PAP for generic amlodipine because generic pricing has made PAPs redundant for this molecule. However, some Indiana community health centers receive 340B drug pricing, which can further reduce cost for qualifying patients. [14]

Indiana's 340B Program. Federally qualified health centers (FQHCs) across Indiana, including HealthNet, Eskenazi Health, and Centerstone, participate in the 340B program, which allows them to acquire medications at deeply discounted prices and pass savings to uninsured or underinsured patients. A patient receiving care at an FQHC may pay $0 to $3 for amlodipine through the 340B mechanism. [15]

Manufacturer Savings Cards. Pfizer offers a savings card for branded Norvasc that may reduce cost for commercially insured patients who are prescribed the brand for a documented medical reason. The card does not apply to Medicaid or Medicare Part D. Because the generic is equally effective and far cheaper, savings cards for the brand are rarely clinically relevant.

State Pharmaceutical Assistance Programs. Indiana does not operate a broad state pharmaceutical assistance program equivalent to those in Pennsylvania (PACE) or New Jersey (PAAD). Hoosiers aged 65 and older who do not qualify for Medicare Part D Extra Help may benefit from reviewing low-premium Part D plans that list amlodipine at $0 copay, rather than seeking a separate state program. [16]

How Does Amlodipine Pharmacology Affect Prescribing Decisions in Indiana?

Amlodipine is a long-acting dihydropyridine calcium channel blocker. It blocks L-type calcium channels in vascular smooth muscle and cardiac muscle, reducing peripheral vascular resistance and lowering systolic and diastolic blood pressure. The plasma half-life of 35 to 50 hours allows once-daily dosing, and the slow onset of action minimizes reflex tachycardia compared with shorter-acting CCBs. [17]

The FDA approved amlodipine in 1992 for hypertension and chronic stable angina. The approved dose range is 2.5 mg to 10 mg once daily. Starting doses for hypertension are typically 5 mg, titrated to 10 mg if blood pressure remains above goal after two to four weeks. [8]

Common adverse effects include peripheral edema (reported in 1.8% at 5 mg and 10.8% at 10 mg in premarketing trials), flushing, and palpitations. [8] Edema is dose-dependent and results from precapillary vasodilation rather than fluid retention. Combining amlodipine with an ACE inhibitor (for example, amlodipine plus benazepril, marketed as Lotrel) reduces edema incidence compared with amlodipine monotherapy, as shown in the ACCOMPLISH trial (N=11,506), where the amlodipine-benazepril combination reduced cardiovascular events by 19.6% compared with benazepril plus hydrochlorothiazide over a mean 36-month follow-up (P<0.001). [18]

Amlodipine is primarily metabolized by CYP3A4. Coadministration with strong CYP3A4 inhibitors such as clarithromycin, ketoconazole, or ritonavir may increase amlodipine exposure and blood pressure-lowering effect. Simvastatin dose should be capped at 20 mg daily when used concurrently with amlodipine 10 mg, per FDA labeling, because amlodipine inhibits simvastatin metabolism and raises the risk of myopathy. [8] [19]

The ACCOMPLISH trial data also demonstrated that the fixed-dose combination of amlodipine 5 mg plus benazepril 20 mg is available as generic Amlodipine/Benazepril at Indiana pharmacies for approximately $12 to $18 per month, only modestly higher than amlodipine monotherapy. [20]

How Does Indiana Compare to Neighboring States on Amlodipine Pricing?

Across the Midwest, generic amlodipine pricing is nearly flat because retail pharmacy pricing in the generic space is driven by national PBM contracts rather than state-level factors. Ohio, Michigan, Illinois, and Kentucky all show cash prices of $6 to $12 per month for generic amlodipine 5 mg or 10 mg at major chains. Indiana's $8 average sits within that range. [21]

The meaningful interstate difference lies in Medicaid coverage. Illinois Medicaid covers amlodipine for hypertension without the type 2 diabetes restriction that Indiana applies. Ohio Medicaid similarly lists it as a preferred agent for hypertension. Indiana Medicaid's narrower indication coverage means that Indiana Medicaid enrollees with hypertension alone must pay out of pocket, use a discount card, or manage a prior authorization process that their counterparts in Illinois or Ohio do not face. [22]

For uninsured Hoosiers, the practical cost is low regardless of state comparison. The $8 cash price at Indiana retail pharmacies makes amlodipine affordable for most patients without any assistance program.

What Should Indiana Patients Discuss with Their Prescriber?

Blood pressure goals set by the 2017 ACC/AHA hypertension guidelines define stage 1 hypertension as a systolic of 130 to 139 mm Hg or diastolic of 80 to 89 mm Hg, and stage 2 as systolic 140 mm Hg or higher or diastolic 90 mm Hg or higher. [3] Patients with stage 2 hypertension or those with diabetes or chronic kidney disease benefit most clearly from amlodipine added to or substituted for a first-line agent.

Indiana patients should ask their prescriber four specific questions before starting amlodipine. First, whether their specific blood pressure pattern (isolated systolic, combined systolic and diastolic, or white-coat hypertension) makes a CCB the optimal class. Second, whether CYP3A4 drug interactions apply to their current medication list, particularly statin and antifungal use. Third, whether a fixed-dose combination with an ACE inhibitor or ARB would reduce pill burden and edema risk. Fourth, whether their Indiana insurance plan requires a step-therapy trial before CCB authorization, and whether their prescriber can document a rationale to bypass that step if clinically appropriate. [23]

The SPRINT trial (N=9,361) found that targeting a systolic blood pressure below 120 mm Hg in adults aged 50 and older with elevated cardiovascular risk reduced major cardiovascular events by 25% and all-cause mortality by 27% compared with targeting below 140 mm Hg, at the cost of slightly higher rates of adverse events including hypotension and syncope. [24] Amlodipine was one of the study drugs permitted for use. That trial reinforced aggressive blood pressure targets for higher-risk patients, a consideration for Indiana providers managing patients with established coronary artery disease or chronic kidney disease.

For Indiana patients paying $8 per month cash, initiating amlodipine without waiting for prior authorization to resolve is often the most direct clinical path. The prescriber documents the visit, the patient fills the prescription that day, and blood pressure re-check occurs in two to four weeks to assess response and tolerability.